Seek Returns

MRNA vs. PCVX: Moderna vs. Vaxcyte Stock Comparison

How do Moderna (MRNA) and Vaxcyte (PCVX) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Moderna (MRNA) and Vaxcyte (PCVX) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Company profile comparison for Moderna (MRNA) and Vaxcyte (PCVX)
Profile ItemMRNAPCVX
NameModerna Inc.Vaxcyte Inc.
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyBiotechnology
GICS Sub-IndustryBiotechnologyBiotechnology
Market Capitalization101.48 billion USD10.11 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateDecember 7, 2018June 12, 2020
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

MRNA
PCVX
GSPC
Loading price history…
Moderna (MRNA) vs. Vaxcyte (PCVX), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Moderna (MRNA) and Vaxcyte (PCVX). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Moderna (MRNA) and Vaxcyte (PCVX). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Moderna (MRNA) and Vaxcyte (PCVX)
MetricMRNAPCVX
Total Return (1Y)1,031.66%59.00%
Total Return (3Y, Annualized)58.68%11.29%
Total Return (5Y, Annualized)3.23%21.60%

Risk Profile

Drawdown History

MRNA
PCVX
GSPC
Loading price history…
Moderna (MRNA) vs. Vaxcyte (PCVX), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Moderna (MRNA) and Vaxcyte (PCVX). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Moderna (MRNA) and Vaxcyte (PCVX)
MetricMRNAPCVX
Volatility (1Y, Annualized)194.88%56.01%
Beta (5Y)1.081.26
Max Drawdown (5Y)-93.93%-76.22%
Avg. Volume (3M)21.61M2.12M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
MRNA and PCVX are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Moderna (MRNA) and Vaxcyte (PCVX)
MetricMRNAPCVX
Sharpe Ratio (1Y)5.270.98
Sortino Ratio (1Y)20.441.76

Profitability

ROE (TTM)

Both Moderna (MRNA) at -39.00% and Vaxcyte (PCVX) at -42.68% report negative ROE values. Negative ROE can reflect losses or negative shareholders’ equity, so both readings need extra context.

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

-39.00%

Max
109.18%
Q3
6.23%
Median
-26.66%
MRNA
-39.00%
Q1
-64.05%
Min
-167.77%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

-42.68%

Max
109.18%
Q3
6.23%
Median
-26.66%
PCVX
-42.68%
Q1
-64.05%
Min
-167.77%
Loading chart…
Moderna (MRNA) vs. Vaxcyte (PCVX): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Moderna (MRNA) reports a negative net margin of -141.43%, usually indicating a net loss over the period. Meanwhile Vaxcyte (PCVX) reports 0.00%, ranking against industry peers normally.

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

-141.43%

Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
MRNA
-141.43%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max
18.05%
Q3
4.78%
PCVX
0.00%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Moderna (MRNA) vs. Vaxcyte (PCVX): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Moderna (MRNA) reports a negative operating margin of -557.93%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Vaxcyte (PCVX) reports 0.00%, ranking against industry peers normally.

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

-557.93%

Max
83.12%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
MRNA
-557.93%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max
83.12%
Q3
14.77%
PCVX
0.00%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Moderna (MRNA) vs. Vaxcyte (PCVX): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Moderna (MRNA) and Vaxcyte (PCVX)
MetricMRNAPCVX
ROE (TTM)-39.00%-42.68%
ROA (TTM)-13.26%-24.98%
Net Margin (TTM)-141.43%0.00%
Operating Margin (TTM)-557.93%0.00%
Gross Margin (TTM)-66.02%0.00%

Growth

Revenue Growth

Only one side can be read here: Moderna (MRNA) reports revenue growth of -39.92%, ranked against its industry; Vaxcyte (PCVX) has no revenue growth figure this period.

Loading chart…
Moderna (MRNA) vs. Vaxcyte (PCVX): A comparison of their Revenue Growth across different time periods.

EPS Growth

Neither Moderna (MRNA) nor Vaxcyte (PCVX) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Growth metrics for Moderna (MRNA) and Vaxcyte (PCVX)
MetricMRNAPCVX
Revenue Growth (YoY)-39.92%--
Revenue Growth (3Y CAGR)-53.30%--
EPS Growth (YoY)----
EPS Growth (3Y CAGR)----

Financial Strength

Current Ratio (MRQ)

Vaxcyte (PCVX) at 4.56 keeps current ratio within its industry’s typical mid-range, while Moderna (MRNA) at 2.30 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for MRNA.

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.30

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
MRNA
2.30
Min
0.10

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.56

Max
25.13
Q3
12.13
Median
5.52
PCVX
4.56
Q1
2.47
Min
0.10
Loading chart…
Moderna (MRNA) vs. Vaxcyte (PCVX): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Moderna (MRNA) at 0.19 and Vaxcyte (PCVX) at 0.09 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.19

Max
1.42
Q3
0.65
MRNA
0.19
Median
0.15
Q1
0.02
Min
0.00

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.09

Max
1.42
Q3
0.65
Median
0.15
PCVX
0.09
Q1
0.02
Min
0.00
Loading chart…
Moderna (MRNA) vs. Vaxcyte (PCVX): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Moderna (MRNA) and Vaxcyte (PCVX)
MetricMRNAPCVX
Current Ratio (MRQ)2.304.56
Debt / Equity (MRQ)0.190.09
Net Debt / EBITDA----

Dividends

Dividend Yield (TTM)

Neither Moderna (MRNA) nor Vaxcyte (PCVX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MRNA
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

PCVX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Moderna (MRNA) vs. Vaxcyte (PCVX): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Moderna (MRNA) nor Vaxcyte (PCVX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MRNA
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

PCVX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Moderna (MRNA) vs. Vaxcyte (PCVX): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Moderna (MRNA) and Vaxcyte (PCVX)
MetricMRNAPCVX
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

P/E Ratio (TTM)

Neither Moderna (MRNA) nor Vaxcyte (PCVX) reports a P/E ratio value for this period, so a direct comparison isn’t possible.

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
MRNA
--

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
PCVX
--
Loading chart…
Moderna (MRNA) vs. Vaxcyte (PCVX): Neither stock reports P/E ratio, so the chart shows available benchmark boxes without value markers.

P/S Ratio (TTM)

A sales-based read is only available for Moderna (MRNA), whose P/S ratio of 45.55 ranks against industry peers; Vaxcyte (PCVX) reports no figure this period.

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

45.55

Max
58.18
MRNA
45.55
Q3
25.77
Median
7.30
Q1
3.01
Min
0.01

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
Min
0.01
PCVX
--
Loading chart…
Moderna (MRNA) vs. Vaxcyte (PCVX): PCVX does not report P/S ratio, so it has no value marker; MRNA is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/B Ratio (MRQ)

Vaxcyte (PCVX) at 3.83 is valued about in line with its industry on P/B ratio, while Moderna (MRNA) at 11.58 carries an above-peer premium to book — MRNA is pricier on assets.

MRNA

Pharmaceuticals, Biotechnology & Life Sciences industry group

11.58

Max
13.53
MRNA
11.58
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.83

Max
13.53
Q3
6.54
PCVX
3.83
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
Moderna (MRNA) vs. Vaxcyte (PCVX): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Moderna (MRNA) and Vaxcyte (PCVX)
MetricMRNAPCVX
P/E Ratio (TTM)----
P/S Ratio (TTM)45.55--
P/B Ratio (MRQ)11.583.83
Free Cash Flow Yield (TTM)0.29%-5.24%